Ignite Creation Date:
2024-05-06 @ 8:07 PM
Last Modification Date:
2024-10-26 @ 3:21 PM
Study NCT ID:
NCT06263543
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2024-02-09
Brief Title:
Sequencing Antibody Drug Conjugates in ERHER2 LOW MBC
Sponsor:
Reshma L Mahtani DO
Organization:
Baptist Health South Florida
Study Overview
Official Title:
SERIES SEquencing Sacituzumab Govitecan AfteR T-DXd In ERHER2 LOW MetaStatic Breast Cancer
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SERIES
Brief Summary:
The purpose of this research study is to see if the medication sacituzumab govitecan SG is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan T-DXd for the treatment of metastatic hormone receptor positive HRhuman epidermal growth factor 2 low HER2 low breast cancer Although SG is approved to treat metastatic HRHER2 negative breast cancer the aim of this study is to determine if SG is still effective specifically in people who have already received T-DXd
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None